The current trial aims to assess the effect of istaroxime in patients with SCAI Stage C Cardiogenic Shock (CS). These patients look unwell, frequently with a sudden change in mental status, mottled and cool extremities, and delayed capillary refill, as well as signs of congestion and relative low blood pressure and signs of hypoperfusion (reduced oxygen to organs) which frequently require support with rescue therapies including inotropes, vasopressors, or mechanical devices.
Windtree Therapeutics, Inc. has been studying istaroxime, which has the potential to treat patients in this condition without some of the disadvantages of existing therapies being used to treat patients with acute heart failure and CS.
Participants enrolled in this trial will receive standard of care (SoC) therapy for heart failure and CS. Additionally, half of the participants will be randomly chosen to receive istaroxime. Istaroxime has the potential to increase blood pressure and improve cardiac function.

开始日期2024-06-01

申办/合作机构

Windtree Therapeutics, Inc.

NCT04325035

/ Completed临床2期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)

This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.

开始日期2020-09-28

申办/合作机构

Windtree Therapeutics, Inc.

[+1]

NCT02617446

/ Completed临床2期

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study

To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle. The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused via i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.

开始日期2015-12-01

申办/合作机构

Windtree Therapeutics, Inc.

100 项与伊司他肟相关的临床结果

登录后查看更多信息

100 项与伊司他肟相关的转化医学

登录后查看更多信息

100 项与伊司他肟相关的专利（医药）

登录后查看更多信息

项与伊司他肟相关的文献（医药）

2026-02-01·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Istaroxime – update of data in early cardiogenic shock and decompensated heart failure

Review

作者: Zimoch, Wojciech ; Biegus, Jan ; Florek, Kamila

INTRODUCTION:

Cardiogenic shock (CS) is the most severe manifestation of acute heart failure (AHF), which is associated with one-year mortality rates of up to 60%. Inotropes are a cornerstone of CS treatment, as they improve central hemodynamics and provide time to address the underlying etiology. Therefore, their early administration, before CS progresses to the neurohumoral and inflammatory phase, is of great importance. Currently used inotropes are associated with adverse events, including tachycardia, ischemia, hypotension, and arrhythmias, and novel medications with a safer and more effective profile are needed. One of promising medications is istaroxime, characterized by a lower risk of malignant arrhythmias and a unique ino-lusitropic mechanism of action.

AREAS COVERED:

This study aimed to describe the mechanism of action of istaroxime and present results from phase II clinical trials on its effectiveness and safety in patients with early CS.

EXPERT OPINION:

Phase II clinical trials demonstrated that istaroxime is effective in the management of early CS (hemodynamic effect). Its advantages stem from a favorable safety profile compared with traditional inotropes, along with proven efficacy in raising systolic blood pressure (SBP) and enhancing central hemodynamics. These effects are mediated through its unique ino-lusitropic mechanism, achieved without increasing heart rate.

2025-12-01·ESC Heart Failure

Haemodynamic Effects of Istaroxime in SCAI Stage B HF-Related Cardiogenic Shock: Insights from the SEISMiC Trial

Article

作者: Takagi, Koji ; Mebazaa, Alexander ; Pagnesi, Matteo ; Ponikowski, Piotr ; Filippatos, Gerasimos ; Zymliński, Robert ; Edwards, Christopher ; Diaz, Maria Luz ; Gulati, Gaurav ; Davison, Beth ; Novosadova, Maria ; Chioncel, Ovidiu ; Biegus, Jan ; Burkhoff, Daniel ; Guardia, Carlos ; Gajewski, Piotr ; Tycińska, Agnieszka ; Cotter, Gad ; Metra, Marco ; Simonson, Steven ; Simmons, Phillip ; Barros, Marianela

Abstract:

Aims:

The haemodynamic effects of istaroxime in SCAI stage B cardiogenic shock (CS) due to acute decompensated heart failure (ADHF) have not been evaluated. We assessed the impact of istaroxime on specific invasively-obtained haemodynamic measures.

Methods and results:

In the SEISMiC extension study, 30 patients with ADHF-related SCAI stage B CS were randomized to 60-h intravenous infusion of either placebo (n = 11) or istaroxime at maximum 0.5–1.0 μg/kg/min (n = 19). In this post hoc analysis, invasively-obtained haemodynamic measures, simulated group-averaged pressure-volume (PV) loops, and end-systolic elastance (Ees), derived from individual-patient PV relationships, were compared between istaroxime- and placebo-treated patients. Compared with placebo, patients randomized to istaroxime for 48–60 h had greater increases in aortic pulsatility index (API) and left ventricular (LV) stroke work index (LVSWI) at 6, 12, 24, and 48 h; and greater increase in pulmonary artery (PA) compliance and reduction in PA elastance at 48 h. At group-averaged PV loop analysis, LV contractility remained stable and right ventricular (RV) contractility tended to deteriorate over time with placebo, whereas LV contractility improved and RV contractility tended to be stabilized with istaroxime. Greater increases in both LV Ees and RV Ees were observed with istaroxime versus placebo from baseline to 48 h.

Conclusions:

In patients with ADHF-pre-CS, istaroxime at doses up to 1.0 μg/kg/min for up to 60 h was associated with sustained improvements in measures of LV performance (API and LVSWI), in parallel with increase in PA compliance and reduction in PA elastance at 48 h. As compared with placebo, istaroxime improved LV contractility and preserved RV contractility, which deteriorated on placebo, over time.

2025-09-23·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

How palytoxin transforms the Na ⁺ ,K ⁺ pump into a cation channel

Article

作者: Toyoshima, Chikashi ; Vilsen, Bente ; Cornelius, Flemming ; Tsunekawa, Naoki ; Kanai, Ryuta

Palytoxin (PTX), a potent marine toxin, has long been known to transform Na + ,K + -ATPase (NKA), an indispensable ion pump, into a nonselective cation channel. It has been postulated that PTX takes control of the two gates on either side of a channel-like pore. These gates normally open and close alternately, synchronized with chemical events, never opening simultaneously. A critical question is whether palytoxin takes over the control of the two gates or creates a new pathway. Here, we present structures of NKA with bound palytoxin in three different states. PTX binds to NKA in E2P, occupying the physiological Na + exit pathway, similar to istaroxime, a new-generation cardiotonic steroid. Adding Na + and ATP/ADP to the NKA·PTX complex induces an open channel traversing the entire membrane alongside the physiological ion pathway. As AlF x , a stable transition state analog of phosphate replaces phosphate in the NKA·PTX complex preformed in E2P, the complex appears to undergo the normal reaction cycle from E2P to E1· n Na + . PTX occupies the space between the transmembrane helices M4 and M6, thereby preventing the closure of the extracellular half of the ion pathway. These structures demonstrate that the architecture of NKA is fundamentally different from “a pore with two gates.” Each half of the ion pathway comprises three segments, including a movable component that plays a pivotal role in translocating the bound cations by connecting the constant part to an appropriate inlet. The ion pathway of NKA transforms dynamically, ensuring that the two halves never exist simultaneously.

108

项与伊司他肟相关的新闻（医药）

2026-04-01

·搜狐新闻

讯科标准检测：注射剂瓶用覆膜胶塞穿刺落屑测试全解析

在制药行业，尤其是注射剂领域，药品的质量与安全是绝对不可逾越的生命线。其中，直接与药液接触的包装组件——胶塞，其性能至关重要。覆膜胶塞作为一种先进的解决方案，通过在传统橡胶胶塞表面覆上一层聚合物薄膜（如聚对二甲苯、特氟龙或多种烯烃共聚物），旨在显著降低胶塞与药物之间的相互作用（如吸附、浸出），并改善其机械性能。然而，无论胶塞的配方与结构如何优化，其一项核心功能——在被注射针头反复穿刺时，能否保持完整、不产生可见或不可见的落屑，始终是评价其安全性的关键指标。穿刺落屑不仅可能直接污染药液，形成不溶性微粒，若随药液进入人体血管，更可能引发毛细血管栓塞、肉芽肿等严重临床风险。因此，科学、严谨的穿刺落屑测试是覆膜胶塞从研发、质控到上市放行各环节都必须通过的“大考”。一、落屑的风险与测试的必要性注射剂在临床使用前，需经过多次穿刺操作：生产线上的一次穿刺灌装与加塞，以及临床使用时护士的二次穿刺注射。每一次穿刺，都是针头对胶塞材料的一次剪切与挤压。若胶塞材料韧性不足、覆膜结合不牢或结构设计存在缺陷，极易产生微粒脱落。这些脱落的微粒可能来自橡胶基体，也可能来自覆膜层本身，其尺寸从肉眼可见到亚微米级不等。药典与药品监管机构（如FDA、EMA、NMPA）对注射剂中的不溶性微粒有严格的限量规定。因此，穿刺落屑测试不仅是评价胶塞性能的“试金石”，更是保障患者用药安全、控制药企合规风险的核心技术屏障。二、测试标准与方法学目前，国际上针对胶塞穿刺落屑的测试已形成较为成熟的标准化方法，主要依据包括： ISO 8871：这个系列标准是针对非肠道和注射器械用弹性件的权威国际标准。其部分章节详细规定了穿刺落屑的测试方法，包括测试装置、穿刺次数、溶液收集及微粒计数的具体规程。它通常要求使用特定的穿刺装置，模拟垂直穿刺动作，并使用纯净的冲洗液（如注射用水）收集穿刺过程中可能产生的落屑。 USP <381> 弹性体密封件：美国药典专论中明确规定了用于注射剂包装的弹性体密封件（即胶塞）的测试要求，其中穿刺落屑是必检项目。其方法与ISO标准原理相似，但在具体参数（如穿刺力、穿刺速度）和合格判定上具有自身特点，是产品进入美国市场必须遵从的准则。 EP 3.2.9 橡胶密封件：欧洲药典的要求同样严格，与ISO标准紧密接轨，构成了欧盟市场的准入基础。各国药典与客户特定要求：许多大型制药企业会根据自身产品特性（如生物制剂、高价值药品）制定更为严苛的内控标准，可能涉及更多的穿刺次数、更严的微粒尺寸控制范围或对特定材质落屑的鉴别。标准的测试流程通常包括以下步骤：样品准备：将覆膜胶塞按规定方法装配到洁净的注射剂瓶（或模拟瓶）上。穿刺操作：在标准化的测试设备上，使用规定规格（如外径0.8mm的针头）的专用穿刺针，以恒定的速度和垂直角度，对胶塞的同一部位或不同部位进行规定次数（如单次、多次，通常为10次）的穿刺。落屑收集：穿刺后，向瓶内注入定量的洁净冲洗液，通过摇晃、超声或其他方式，将可能脱落并附着在胶塞、瓶壁或针头上的微粒全部冲洗至液体中。微粒分析与计数：使用符合药典要求的微粒分析仪（如光阻法颗粒计数器）对收集液进行分析，统计≥10μm和≥25μm的微粒数量。有时还需通过显微镜检查进行形态确认或对更大尺寸的可见异物进行人工判定。三、关键影响因素与测试深度解读一次完整的穿刺落屑测试，其价值远不止于获得一组“合格/不合格”的数据。深入分析测试过程与结果，能揭示众多关键信息：胶塞材料与配方：橡胶基体的成分、硫化程度、填充剂，以及覆膜材料的种类、厚度、与基体的粘合力，是决定抗穿刺性的根本。测试可对比不同配方和工艺的优劣。针头特性：针头的外径、斜面设计（如铅笔尖式、反斜面式）、锋利度及表面润滑处理，会极大影响穿刺时的切割力和摩擦力。测试需模拟临床最常用的针型。穿刺参数：穿刺速度、穿刺力、停留时间以及是否旋转拔针，都会影响落屑的产生。标准化的设备确保了这些参数的可控与可重复。测试的严苛性：除了标准次数，增加穿刺次数至20次、50次甚至更多，可以评估胶塞在极端或重复使用场景下的耐久性极限，为高风险药品提供额外的安全余量。四、行业趋势与挑战随着高风险制剂（如单克隆抗体、疫苗、细胞治疗产品）的蓬勃发展，对包装系统的要求达到了前所未有的高度。行业趋势正朝着“零落屑”或“近零落屑”的目标迈进。这驱动着覆膜胶塞技术的持续创新，如开发更坚韧的复合膜层、自密封材料等。同时，监管机构对数据完整性和质量源于设计（QbD）理念的强调，也要求测试过程必须高度可靠、数据必须完全可追溯。这不仅对胶塞生产商，也对制药企业的来料质量控制实验室提出了更高的技术能力要求。许多企业选择与具备顶尖设备和深厚经验的第三方检测机构合作，以获取客观、公正、符合全球标准的数据，加速研发进程并确保供应链的稳定与安全。包装组件的微小瑕疵，可能关乎患者的健康与生命的尊严。专业的穿刺落屑测试，是隐藏在每一支注射剂背后的重要安全守护。通过精准的测试、客观的数据与深入的分析，可以为药品包装的合规性、安全性与可靠性提供坚实的科学证据。讯科标准检测ISTA认可实验室 | CMA | CNAS地址：深圳宝安服务范围：穿刺落屑测试、密封完整性测试、包装材料相容性研究、医药包装检测标准咨询欢迎联系讯科标准检测，了解更多关于医药包装检测的信息。返回搜狐，查看更多

2026-03-30

·PRNewswire

Panacea Capital Leads Formation of Seismic Pharma to Advance Novel, Clinical-Stage Heart Failure Portfolio

New company formed to unlock value from Phase 3-ready and next-generation therapies for cardiogenic shock and acute heart failure Targeting completion of first Phase 3 study for istaroxime to enable NMPA registration by 2027 Advancing next-generation oral heart failure program towards first-in-human studies by 2027 DURHAM, N.C. and SINGAPORE, March 30, 2026 /PRNewswire/ -- Seismic Pharma, a newly formed biopharmaceutical company, today announced its launch and initial financing led by Panacea Capital. The company has been formed to advance a portfolio of clinically validated and next-generation drug candidates for the treatment of heart failure acquired from Windtree Therapeutics. Seismic Pharma's lead program, istaroxime, is a Phase 3-ready, first-generation calcitrope for cardiogenic shock with extensive clinical data demonstrating its ability to improve hemodynamic stability and cardiac function, without the safety limitations associated with conventional inotropic therapies. Together with next-generation compounds targeting acute and advanced heart failure, the company's portfolio is aimed at addressing critical gaps in patient care across both inpatient and outpatient settings. "With no approved therapeutics, cardiogenic shock is the last major frontier in treating heart failure. More broadly, acute heart failure and advanced heart failure remain some of the most significant unmet needs in cardiovascular medicine, yet no medications have been approved for these conditions in decades. We believe our portfolio represents a compelling opportunity to deliver meaningful new options for patients," said Gad Cotter, MD. "At Panacea Capital, we build companies around high-conviction therapeutic assets, and Seismic Pharma represents a clear opportunity to do exactly that," said James Huang, Founder and Managing Partner of Panacea Capital. "Gad and the team bring deep domain expertise and a track record of translating clinical insight into successful development programs and strategic exits. We are excited to partner closely with them to advance Seismic's portfolio efficiently toward key clinical milestones." About Seismic Pharma Seismic Pharma is a biopharmaceutical company dedicated to advancing novel treatments for heart failure. The company combines deep therapeutic expertise with a proven track record in acute heart failure drug development. Seismic Pharma's founding portfolio of drug candidates was acquired from Windtree Pharmaceuticals and will be advanced toward clinical development with the support of a board of directors with extensive experience in successful heart failure programs. The company is headquartered in Durham, North Carolina About Panacea Capital Panacea Capital is a global life sciences investment firm that builds and scales innovative companies across therapeutic and adjacent healthcare opportunities, unified by an asset-centric and execution-driven approach. The firm invests across private and public markets and works closely with management teams to shape strategy, structure capital, and drive execution from early development through commercialization. With deep experience in drug development and cross-border execution, Panacea Capital operates seamlessly across the U.S. and Asia to accelerate development timelines, enhance capital efficiency, and expand access to regulatory and commercial opportunities. Contact: Gad Cotter, Seismic Pharma – [email protected] SOURCE Seismic Pharmaceuticals 21% more press release views with Request a Demo

临床3期

2025-09-04

·PRNewswire

Late Breaking Clinical Research Coming to Heart Failure Society of America Annual Scientific Meeting September 26-29

WASHINGTON, Sept. 4, 2025 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 26-29, at the at the Minneapolis Convention Center in Minneapolis, MN. Late breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Continue Reading Heart Failure Society of America Annual Scientific Meeting 2025 takes place September 26-29 in Minneapolis, MN. Sunday, September 28 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 1: Devices and Cardiomyopathies Integra-D Trial Effects of a Novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on NYHA Functional Class in ICD-Indicated Patients: Post-Implant Results from the Integra-D Trial FUTURE-HF Development of an Individualized Congestion Score using a Novel Implantable Inferior Vena Cava Sensor: the FUTURE-HF Trial Portfolio DETECT-HF Development and Training of a Voice-Based Algorithm for Heart Failure Monitoring: Performance results from 599 Patients over 360,000 Patient-Days FOREST-HCM Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: a 96-week analysis from FOREST-HCM MAPLE-HCM Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM ATTRibute-CM Acoramidis Reduces Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM HELIOS-B Reduction in Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B Monday, September 29 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 2: Novel Therapies VICTOR Trial Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients with HFrEF Enrolled in the VICTOR trial Tolerability and Safety of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction SEISMiC C Safety and Efficacy of Intravenous Administration of Istaroxime for 48 hours in Patients with SCAI C Cardiogenic Shock due to Acute Heart Failure SUMMIT Trial Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis from the SUMMIT Trial GARDEN TIMI-74 GDF-15 Neutralization in Patients with Heart Failure: Primary Results of the GARDEN-TIMI 74 Trial Danicamtiv Trial Danicamtiv Restores Ventricular and Atrial Function in Patients with Dilated Cardiomyopathy Caused by Genetic Variants that Depress Sarcomere Function Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Due to the quantity of remarkable trials submitted, HFSA will also feature late breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday September 28 | Rapid Fire 1 | 10:45 AM - 11:45 AM Phase 1 Study of Daratumumab-Hyaluronidase for Reduction of Circulating Antibodies in Patients with High Allosensitization Awaiting Heart Transplantation Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Post-Heart Transplant Patients: A Multi-Center Retrospective Cohort Study Long Term Outcomes after LVAD Weaning for Myocardial Recovery: Results from the VAD Wean Recovery Network First-In-Human Implantation of a Next-Generation Membrane-Based LVAD Long Term Trajectory of Glomerular Filtration Rate Post-LAVD and the Impact on Clinical Outcomes: An analysis of the MOMEMTUM 3 Study Increased LVEF at Six Months Following LVAD Implant is Associated with Improved Long-Term Outcomes - A MOMENTUM-3 Analysis Screening for advanced heart failure in stable outpatients (The SAINTS study) Sunday, September 28 | Rapid Fire 2: | 2:15 PM - 3:15 PM Clinical Outcomes for Heart Failure at High Risk of Hyperkalemia according to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System Intravenous Ferric Carboxymaltose in Patients With Ischemic Versus Non-Ischemic Etiology of Heart Failure and Iron Deficiency Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB High-Dose IV Loop Diuretic Therapy and Ototoxicity Risk in Patients with Acute Heart Failure: Insights from the FASTR Trial Expanded Results from a Guideline-Directed Medical Therapy Clinic Optimized Heart Failure Therapy in Patients at Risk of Cardiac Wasting in Patients with Advanced Cancer: Results from the EMPATICC trial Supervised Exercise Training Improves Outcomes in Heart Failure: Evidence from the PACT-HF 2×2 Factorial Trial Sunday, September 28 | Rapid Fire 3 | 4:15 PM - 5:15 PM Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset PROACTIVE-HF: 2-year outcomes, stratified by LVEF Outcomes of Poor Clinical Responders After Transcatheter Aortic Valve Replacement in Older Patients Invasive Hemodynamic Risk Stratification and Transcatheter Edge-to-Edge Tricuspid Repair: One-Year Results from TRILUMINATE Pivotal Trial Relationship between changes in seated pulmonary artery pressure, blood pressure, heart rate, and weight prior to heart failure hospitalization A Randomized Trial of a Remote, Digital Intervention Targeting Heart Failure Medical Therapy Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-invasive Multisensor Device Deep learning assisted prediction for occurrence of pacing-induced cardiomyopathy in the atrio-ventricular block Monday, September 29 | Rapid Fire 4 | 12:00 PM – 1:00 PM Effect of vericiguat, compared with placebo, across baseline risk categories in chronic heart failure with reduced ejection fraction in the VICTOR Trial Effect of Vericiguat on Heart Failure Hospitalisation Events in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Effect of Vericiguat on Mortality in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Regional Variation in Outcomes and Response to Vericiguat in Heart Failure with Reduced Ejection Fraction: The VICTOR Trial Effect of the Soluble Guanylate Cyclase Stimulator Vericiguat on Health Status in the Phase 3 VICTOR Trial The Effect of Vericiguat on Mode of Death in Patients with Heart Failure with Reduced Ejection Fraction in the VICTOR Trial Rapidity of benefit of simultaneous initiation of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: the CONFIDENCE trial Dapagliflozin in Patients with Heart Failure: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 The meeting kicks off in just three weeks. A full schedule at a glance is available online, as well as information on the science and research and networking available at the meeting. Learn more about the meeting and register at hfsa.org/asm2025. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected] SOURCE Heart Failure Society of America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期临床1期

100 项与伊司他肟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	伊司他肟	-	DB06157

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
休克	临床2期	美国	Windtree Therapeutics, Inc.	2020-09-28
休克	临床2期	阿根廷	Windtree Therapeutics, Inc.	2020-09-28
休克	临床2期	意大利	Windtree Therapeutics, Inc.	2020-09-28
休克	临床2期	波兰	Windtree Therapeutics, Inc.	2020-09-28
心源性休克	临床2期	美国	Windtree Therapeutics, Inc.	2020-09-28
心源性休克	临床2期	阿根廷	Windtree Therapeutics, Inc.	2020-09-28
心源性休克	临床2期	意大利	Windtree Therapeutics, Inc.	2020-09-28
心源性休克	临床2期	波兰	Windtree Therapeutics, Inc.	2020-09-28
急性失代偿性心力衰竭	临床2期	-	Debiopharm International SA	2009-06-01
心脏衰竭	临床2期	-	-	2006-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04325035 (SEISMiC, GlobeNewswire) 人工标引	临床2期	心源性休克	20	Istaroxime	膚鬱襯齋壓憲醖鹽網繭(簾繭蓋範餘簾艱壓顧鹽) = There were no new safety concerns identified, and no apparent excess arrhythmias in patients treated with istaroxime when given with standard of care therapies. The effects on hemodynamic and echocardiographic measures appeared to be consistent with results seen in previous istaroxime studies. 願鹽窪選糧齋窪選遞鏇 (鏇衊製觸繭簾窪鏇繭鹹 )	积极	2025-08-05
				Placebo
NCT04325035 (SEISMiC, GlobeNewswire) 人工标引	临床2期	心脏衰竭	30	Istaroxime	壓觸鹹淵膚憲積醖襯製(遞構遞築鹽夢網鑰顧壓) = 簾網齋憲壓積願艱衊憲窪範顧夢獵艱醖艱膚壓 (廠淵餘顧顧製窪鬱壓築 ) 更多	积极	2024-09-30
				Placebo	壓觸鹹淵膚憲積醖襯製(遞構遞築鹽夢網鑰顧壓) = 醖蓋廠糧構簾蓋壓鹽積窪範顧夢獵艱醖艱膚壓 (廠淵餘顧顧製窪鬱壓築 ) 更多
NCT02617446 (CTgov)	临床2期	急性失代偿性心力衰竭	120	Istaroxime (Istaroxime 0.5 µg/kg/Min)	淵獵遞糧選選壓選艱鏇(淵觸餘糧憲蓋築壓鏇襯) = 網鏇願網衊鬱觸醖齋鏇鹽廠選膚襯壓艱製鏇艱 (積鏇醖積簾膚鬱鬱選積, 蓋鬱選觸製獵糧壓醖膚 ~ 構窪鏇鹹廠繭夢壓蓋鏇) 更多	-	2023-05-24
				Istaroxime (Istaroxime 1.0 µg/kg/Min)	淵獵遞糧選選壓選艱鏇(淵觸餘糧憲蓋築壓鏇襯) = 壓繭鬱糧襯窪築糧窪夢鹽廠選膚襯壓艱製鏇艱 (積鏇醖積簾膚鬱鬱選積, 鏇鑰範窪憲願鹹積廠艱 ~ 鏇繭製憲觸壓壓築壓鏇) 更多
NCT02772068 (Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a, Pubmed \| JACC Heart Fail)	早期临床1期	射血分数保留型心力衰竭	26	Istaroxime 0.5 mg/kg/min	壓衊構壓鹽憲鹽獵壓鹽(壓鬱製鹽築願窪艱鹹範) = 構獵夢襯築選廠顧膚鹹艱衊糧憲構襯齋選憲鑰 (蓋顧蓋繭醖膚繭簾窪蓋 ) 更多	-	2023-03-15
				Placebo	壓衊構壓鹽憲鹽獵壓鹽(壓鬱製鹽築願窪艱鹹範) = 網鹹鏇獵憲選顧糧醖壓艱衊糧憲構襯齋選憲鑰 (蓋顧蓋繭醖膚繭簾窪蓋 ) 更多
SEISMiC (Pubmed \| Eur J Heart Fail)	临床2期	-	-	Istaroxime 1.0-1.5 μg/kg/min	繭鑰醖範廠觸鹹糧築製(襯構觸鹹憲醖襯艱繭製) = 選遞憲艱醖簾鑰廠壓範窪鬱願襯餘鏇糧遞淵願 (醖醖鹽觸膚淵窪蓋淵艱, 6.88) 更多	积极	2022-10-01
				Placebo	繭鑰醖範廠觸鹹糧築製(襯構觸鹹憲醖襯艱繭製) = 簾繭顧積餘淵簾觸簾壓窪鬱願襯餘鏇糧遞淵願 (醖醖鹽觸膚淵窪蓋淵艱, 6.76)
NCT04325035 (SEISMiC, Pubmed) 人工标引	临床2期	心脏衰竭 \| 休克	60	istaroxime	製夢艱構憲網鑰鏇顧願(膚顧艱獵顧範顧壓艱鑰) = 鹽製鬱構淵艱鹹淵獵壓簾鹽鬱艱網壓齋淵簾鏇 (膚鏇夢築淵壓蓋壓蓋鹹, 6.88) 更多	积极	2022-07-22
				Placebo	製夢艱構憲網鑰鏇顧願(膚顧艱獵顧範顧壓艱鑰) = 鹹築遞醖築構壓範憲窪簾鹽鬱艱網壓齋淵簾鏇 (膚鏇夢築淵壓蓋壓蓋鹹, 6.76) 更多
NCT04325035 (SEISMiC, Biospace) 人工标引	临床2期	心脏衰竭 \| 心源性休克	60	Istaroxime	鏇襯淵醖鹽衊獵淵膚膚(醖夢製築憲鏇遞網衊鏇): P-Value = 0.017 更多	积极	2022-05-23
				Placebo
NCT00616161 (HORIZON-HF, Pubmed \| J Am Coll Cardiol)	临床2期	心脏衰竭	120	Istaroxime	膚廠壓顧膚築製繭願顧(窪鏇鹹構壓觸壓築鏇構) = 壓選顧網蓋糧鹽淵鏇選鏇鏇鏇襯艱廠糧鹽憲網 (餘構齋觸積選觸糧廠餘 )	-	2008-06-10